Subscribe to Search results

Richard Ashcroft

Published on:

Emma Cave

Published on:

Melinee Kazarian

Published on:

Anne-Maree Farrell

Published on:

Julian Savulescu

Published on:

David Armstrong

Published on:

Sir David Spiegelhalter

Published on:

Jane Anderson

Published on:

Professor Bloom assessed the size of the risk of AIDS by making reference to the number of AIDS cases developed in the UK and Europe amongst people with haemophilia.

Published on:

A memorandum from Dr Peter Foster to John Watt stated the assertion that the risk of contracting AIDS was one in one million.

Published on:

The DHSS produced a public information leaflet for blood donors which stated that "Should just one of the donors be suffering from AIDS, then the Factor VIII could transmit the disease."

Published on:

Minutes of a UKHCDO meeting recorded that Dr Malcolm Chisholm wondered if directors could revert to cryoprecipitate, given the "worry of patients" to which Professor Bloom responded that "he felt there was no need for patients to stop using the commercial concentrates because at present there was no proof that commercial concentrates were the cause of AIDS".

Published on:

At a Reference Centre Directors' meeting, Professor Bloom stated that it was "difficult to avoid the argument that non-HT [non-heat treated] constitutes a risk."

Published on:

The Haemophilia Society informed the DHSS that they wanted to discuss - among other subjects - the "no ban on the importation of American concentrates."

Published on:

Dr Walford referred to "the cries from some quarters to ban the import of Factor VIII". It was not universally accepted at the time.

Published on:

At a meeting of the Blood Products Advisory Committee, Dr Michael Rodell (Armour) indicated that it was clear that pools might have been contaminated. He also stated that persons who were paid for their plasma had it collected 40 to 60 times per year, on average.

Published on:

Professor Bloom wrote to Armour to express concerns that concentrate prepared from plasma collected before March 24 might be preferentially exported from the USA.

Published on:

In a letter, K.W FItch (Armour) stated that Armour had not preferentially exported plasma stocks out of the USA which had been produced from plasma collected prior to the FDA ruling.

Published on:

Dr Walford asked Dr Fowler of Medicines Division whether the supply of blood comprising pre-March plasma could be resisted.

Published on:

Dr Walford considered it possible that concentrates made from the "safer" plasma might be retained for use in the US whilst those older stocks were dumped on export markets such as the UK. Dr Walford also asked if there was any way, perhaps by new labelling requirements to prevent this.

Published on: